1. EMA Reviewing Medicines
Containing Valsartan from Zhejiang Huahai
following Detection of an Impurity: Some Valsartan Medicines Being
Recalled Across the EU. European Medicines
Agency, July 5, 2018. https://www.ema.europa.eu/en/news/ema-reviewing-medicines-containing-valsartan-zhejiang-huahai-following-detection-impurity-some.
2. FDA Provides Update on Its Ongoing Investigation
into Valsartan Products;
and Reports on the Finding of an Additional Impurity Identified in
One Firm’s Already Recalled Products. U.S. Food and Drug Administration, September 13, 2018. https://www.fda.gov/news-events/press-announcements/fda-provides-update-its-ongoing-investigation-valsartan-products-and-reports-finding-additional.
3. FDA Updates and Press Announcements on Angiotensin
II Receptor Blocker
(ARB) Recalls (Valsartan, Losartan, and Irbesartan). U.S. Food and Drug Administration, November 13, 2019. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan#5cc3b83d3b22e.
4. COMMISSION IMPLEMENTING DECISION of 2.4.2019 concerning,
in the framework
of Article 31 of Directive 2001/83/EC of the European Parliament and
of the Council, the marketing authorisations of medicinal products
for human use which contain the active substances “candesartan”,
“irbesartan”, “losartan”, “olmesartan”,
“valsartan”. European Commission, April 4, 2019. https://ec.europa.eu/health/documents/community-register/2019/20190402144194/dec_144194_en.pdf
5. Regulatory Highlights